GlaxoSmithKline is committing $30 billion to expand its U.S. footprint, including a new factory and advanced digital tools, as Washington’s tariff threats push drugmakers to localize production. The move highlights a broader shift of pharmaceutical investment away from the U.K. toward America’s more favorable market conditions.
Factory and Technology Expansion
The London-based pharma giant confirmed $1.2 billion will go toward a new facility in Pennsylvania focused on respiratory and oncology treatments, with construction slated to begin in 2026. Additional funding will deploy artificial intelligence and digital tools across five existing American sites, including operations in North Carolina and Maryland. The company said the remainder of the investment will bolster drug research and strengthen its U.S. supply chain footprint.
The announcement came as U.S. President Donald Trump arrived in the U.K., pressing global drugmakers to shift production stateside under threat of tariffs of up to 250% on imports. British Prime Minister Sir Keir Starmer hailed the investment as proof of “collaboration between the countries” and a boost for innovation and jobs.
Mounting Pressure on the U.K. Sector
While GSK has pledged to maintain more than £1.5 billion ($2 billion) in annual R&D spending in Britain, its U.S. commitment highlights the headwinds facing the U.K. pharma industry. Nearly £2 billion of planned drugmaker investments have been paused or scrapped in Britain this year, including Merck’s decision to abandon a £1 billion London research hub and AstraZeneca’s halt of a £200 million Cambridge expansion.
Industry analysts note that the U.S. market offers faster regulatory approvals, stronger pricing power, and policy backing, factors that make it increasingly attractive compared with the U.K.’s strained environment. According to trade reports, the U.S. has outpaced Europe in pharmaceutical capital expenditure growth over the past decade, with its share of global biopharma R&D spending climbing steadily.
Beyond Tariffs, Global Markets Beckon
Tariffs may be driving factories and research dollars to the U.S., but the fastest-growing demand for medicines will come from Asia and other emerging economies. The real question for GSK and its peers is whether they can build out in America without weakening their presence in regions where growth will be stronger. The companies that strike that balance will be the ones best placed to weather policy swings on both sides of the Atlantic.
